Yaohui G. Xu

Cutaneous Adenoid Cystic Carcinoma with Perineural Invasion Treated by Mohs Micrographic Surgery—A Case Report with Literature Review

We report a 58-year-old woman with cutaneous adenoid cystic carcinoma arising on the chest treated with Mohs micrographic surgery. The patient remained tumor-free at 24-month follow-up. To date, only six other cases of cutaneous adenoid cystic carcinoma were reportedly managed by Mohs surgery. Cutaneous adenoid cystic carcinoma has low potential for distant metastasis but is notorious for its aggressive infiltrative growth pattern, frequent perineural invasion, and high risk of local recurrence after excision. We propose that Mohs surgery is an ideal method to achieve margin-free removal of cutaneous adenoid cystic carcinoma. A brief literature review is provided.

Diagnosis and management of lentigo maligna: a review.

Lentigo maligna is a melanocytic neoplasm occurring on sun-exposed skin, usually on the head and neck, of middle-aged and elderly patients. It is thought to represent the in situ phase of lentigo maligna melanoma. The ill-defined nature and potentially large size of lesions can pose significant diagnostic and treatment challenges. The goal of therapy is to cure the lesions in order to prevent development of invasive disease, and surgical excision is the treatment of choice to achieve clear histological margins. Nonsurgical treatment modalities have been reported; however, evidence is lacking to support their use. Age, general health, and comorbidities need to be taken into account when deciding the right treatment modality for each individual patient.

Biopsy Use in Skin Cancer Diagnosis: Comparing Dermatology Physicians and Advanced Practice Professionals

Author Affiliations: Department of Dermatology, University Clinic of Navarra, Pamplona, Navarra, Spain (Redondo, Gímenez de Azcarate, Aguado); Research Support Service, University Clinic of Navarra, Pamplona, Navarra, Spain (Núñez-Córdoba); Department of Preventive Medicine and Public Health, Medical School, University of Navarra, Pamplona, Navarra, Spain (Núñez-Córdoba); Area of Cell Therapy, University Clinic of Navarra, Pamplona, Navarra, Spain (Andreu, García-Guzman, Prosper).

Ossified soft tissue leiomyoma in a patient with sickle cell anemia

Abstract:  Osseous metaplasia in leiomyomas is extremely rare. Here, we report the case of an ossified subcutaneous leiomyoma in a 34‐year‐old African American man with sickle cell thalassemia who presented with a painful nodule of the scapular region, which appeared as a heavily mineralized soft tissue mass on chest radiographs. Histopathologic and immunohistochemical examination of the resected nodule revealed a benign soft tissue leiomyoma composed of intersecting fascicles of spindle cells that strongly expressed smooth muscle actin and caldesmon. Extensive intratumoral calcification and ossification were noticed. Only eight cases of ossified leiomyoma have been reported, of which two arose in the deep soft tissue. Those cases are briefly reviewed and discussed.

Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors

Melanoma is one of the deadliest forms of skin cancer. Although BRAF inhibitors significantly enhance survival of metastatic melanoma patients, most patients relapse after less than a year of treatment. We previously reported that mRNA binding protein Insulin‐like growth factor 2 mRNA‐binding protein 1 (IGF2BP1) is overexpressed in metastatic melanoma and that expression of IGF2BP1 confers resistance to chemotherapeutic agents. Here we demonstrate that IGF2BP1 plays an important role in the sensitivity of melanoma to targeted therapy. Inhibition of IGF2BP1 enhances the effects of BRAF‐inhibitor and BRAF‐MEK inhibitors in BRAFV600E melanoma. Also, knockdown of IGF2BP1 alone is sufficient to reduce tumorigenic characteristics in vemurafenib‐resistant melanoma. These findings suggest that IGF2BP1 can be a novel therapeutic target for melanoma.

A cystic growth on the lower eyelid: a presentation of two cases.

Case 1 was a 62-year-old man with a history of hypertension and hyperlipidemia that presented with a translucent 8 mm papule on the medial aspect of his left lower eyelid present for nine months (Fig. 1). Previous treatments included a course of doxycycline without improvement. Case 2 was a 57-year-old man with a history of hypertension that presented with an asymptomatic 4 mm papule on the right lower eyelid present for two years.

Erratum to “Pathogen discovery from human tissue by sequence-based computational subtraction” ☆: [Genomics 81 (2003) 329–335]☆

a Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA b Whitehead Institute/MIT Center for Genome Research, Cambridge, MA 02142, USA c Decision Systems Group, Brigham and Women’s Hospital, Boston, MA 02115, USA d Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA e Department of Pathology, Harvard Medical School, Boston, MA 02115, USA f Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02138, USA